title: [Apnea of prematurity: what's new?].
abstract: Prematurity apnea remains a major clinical problem that requires treatment choices which are sometimes difficult. Prematurity apnea occurs in most infants of gestational age at birth less than 33 weeks. It is a developmental disorder which usually reflects a "physiological" immaturity of respiratory control. However, neonatal diseases may be associated and play an additive role, resulting in an increased incidence of apnea. Careful screening should therefore be performed in order to make sure that no other factor than immaturity is involved in the occurrence of apnea. Short apnea (less than 10s, without hypoxemia and bradycardia), due to immaturity, are not clinically relevant. More prolonged apnea, that last for more than 15 or 20s, and / or apnea associated with bradycardia or oxygen desaturation, results in short-term disturbances of cerebral haemodynamics and oxygenation, which may negatively impact on neurodevelopmental outcome. Evaluating the immediate severity of apnea and the risks that apnea may affect long-term outcome remains a challenge. The choice of treatments is based on a few evidences. Caffeine citrate, which reduces the incidence of apnea, has been used for decades. However, a thorough evaluation of risks and benefits of this medication has been performed only recently. Caffeine citrate was found to be safe and resulted in unexpected benefits. In treated infants, compared with controls, indeed, a decreased incidence of the following complications was recorded: bronchopulmonary dysplasia at 36 weeks of conceptional age, patent ductus arteriosus, cerebral palsy at 18 months of age. Nasal CPAP can be used in association with caffeine citrate, when the latter is not effective enough.
authors: Service de médecine néonatale, groupe hospitalier Cochin Saint-Vincent-de-Paul (AP-HP), université Paris-Descartes, 75014 Paris, France. guy.moriette@cch.aphp.fr
authors: G
authors: G
authors: Moriette
authors: S
authors: S
authors: Lescure
authors: M
authors: M
authors: El Ayoubi
authors: E
authors: E
authors: Lopez
mesh_terms: D001049:Apnea / Q000097:blood / Q000188:drug therapy / Q000209:etiology*; D001919:Bradycardia / Q000097:blood / Q000209:etiology; D001925:Brain Damage, Chronic / Q000097:blood / Q000517:prevention & control; D001997:Bronchopulmonary Dysplasia / Q000097:blood / Q000517:prevention & control; D002110:Caffeine / Q000009:adverse effects / Q000627:therapeutic use; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000627:therapeutic use; D002951:Citrates / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D045422:Continuous Positive Airway Pressure; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000097:blood / Q000188:drug therapy / Q000209:etiology*; D015997:Neonatal Screening; D010100:Oxygen / Q000097:blood; D012307:Risk Factors
chemical_list: D000697:Central Nervous System Stimulants; D002951:Citrates; D002110:Caffeine; D010100:Oxygen; C026189:caffeine citrate